Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers help pick best pill form for new drug

NCT ID NCT07240116

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolled 18 healthy adults to compare how the body absorbs miricorilant from different tablet types. Participants received the drug in various forms and doses on separate days. The goal is to find which formulation works best for future trials. This is an early-stage study focused on drug behavior, not treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Miricorilant

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

18 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to understand written informed consent * Willing and able to comply with study requirements * Willing to comply with protocol-specified contraception requirements * Healthy male or non-pregnant, non-lactating female of non-childbearing potential per Investigator assessment. * Body mass index (BMI) of 18.0 to 30.0 kg/m\^2 at screening * Weight of at least 50 kg at screening Exclusion Criteria: * Serious adverse reaction or hypersensitivity to any drug or formulation excipients * History of clinically significant allergy requiring treatment * History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder * Any form of cancer within the 5 years before the first does of this study * History and/or symptoms of adrenal insufficiency * History of clinically significant GI disease * Condition or history of a condition that could be aggravated by glucocorticoid antagonism or glucocorticoid activation * History of additional risk factors for torsades de pointes * Poor venous access that limits phlebotomy * Clinically significant abnormal clinical chemistry, hematology or urinalysis * History or evidence of hypokalemia * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results * Evidence of renal impairment at screening * Positive serum or highly sensitive urine pregnancy test at screening or first admission * Clinically significant ECG abnormalities or vital sign abnormalities at screening or baseline * Received any investigational medicinal products (IMP) in a clinical research study within 5 half-lives or within 30 days prior to first dose * Donation of blood within 2 months or donation of plasma within 1 week prior to first dose of study medication * Are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies in the 14 days before first IMP administration * Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months before first IMP administration or 3 months for inhaled products * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption as defined in the study protocol * A confirmed positive alcohol urine test at screening or first admission * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * A confirmed positive urine cotinine test at screening or first admission * Positive drug screen test result at screening or first admission * Male subjects with pregnant or lactating partners * Study site or Sponsor employee or immediate family members one * Failure to satisfy the Investigator of fitness to participate for any other reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Site 01

    Miami, Florida, 33126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.